AndroGel Monitoring Schedule: Labs, Exams, and Follow-Up Timeline

How AndroGel Works: Mechanism in 90 Seconds

Testosterone gel delivers exogenous testosterone through the stratum corneum into dermal capillaries over roughly 2 to 4 hours. Once absorbed, testosterone binds the androgen receptor in target tissues (muscle, bone, brain, adipose) and is also converted to dihydrotestosterone by 5-alpha reductase and to estradiol by aromatase. The gel produces a relatively steady-state serum concentration within 24 hours, which is why the FDA-approved labeling specifies once-daily dosing.

Peak serum levels arrive 2 to 8 hours post-application for the 1.62% formulation. Trough levels, drawn just before the next dose, are the measurement that matters for dose titration. The Testosterone Trials (TTrials, N=790) confirmed that daily topical testosterone reliably restored serum testosterone into the normal adult male range (400 to 700 ng/dL) over 12 months of use 1.

Because the drug bypasses first-pass hepatic metabolism, liver toxicity is far less common than with oral 17-alpha-alkylated androgens. This pharmacokinetic advantage does not, however, eliminate the need for liver function monitoring. Rare cholestatic hepatitis has been reported with transdermal testosterone in post-marketing surveillance data cataloged by the FDA.

Baseline Labs: What to Draw Before the First Application

No testosterone prescription should be filled until two separate early-morning total testosterone levels confirm hypogonadism (total T below 300 ng/dL on most assays). The Endocrine Society 2018 guideline lists the following baseline panel before initiating therapy:

• Total testosterone (drawn between 7 and 10 AM, fasting preferred)
• Free testosterone or sex hormone-binding globulin (SHBG) if total T is borderline (250 to 350 ng/dL)
• Complete blood count with hematocrit and hemoglobin
• PSA (prostate-specific antigen)
• Comprehensive metabolic panel including hepatic transaminases
• Fasting lipid panel (LDL, HDL, triglycerides)
• Estradiol (to establish a pre-treatment reference)
• LH and FSH (to distinguish primary from secondary hypogonadism)
• Prolactin (if LH/FSH are low, to rule out pituitary pathology)

A digital rectal exam (DRE) is recommended for men over 40 at baseline, per AUA/Endocrine Society consensus. Documenting a baseline hematocrit is non-negotiable. Testosterone stimulates erythropoiesis through EPO upregulation and direct marrow effects, and the most common serious adverse effect of TRT is polycythemia (hematocrit above 54%), which raises the risk of venous thromboembolism.

The 2-to-4-Week Lab Check: First Dose Titration

The first follow-up blood draw should occur 2 to 4 weeks after starting AndroGel. Draw a trough testosterone level (before the morning application). The goal is simple: confirm the patient is absorbing the gel and reaching a trough of 400 to 700 ng/dL.

If trough testosterone is below 400 ng/dL, the dose is typically increased by one pump (the 1.62% formulation delivers 20.25 mg per pump actuation). If it exceeds 700 ng/dL, reduce by one pump. Repeat the trough level 2 weeks after any dose change.

At this visit, also check hematocrit. A rise of more than 3 percentage points from baseline, even if the absolute value stays below 54%, warrants closer monitoring at 6-week intervals. A 2019 meta-analysis in the Journal of Clinical Endocrinology & Metabolism (19 RCTs, N=3,236) found that injectable testosterone caused polycythemia in 11.2% of patients versus 3.4% for transdermal formulations. Gel is safer on this metric, but not safe enough to skip the lab.

The 3-Month Visit: Full Reassessment

Three months marks the first comprehensive re-evaluation. By this point, most clinical benefits (energy, libido, mood) have started to emerge, and most hematologic risks have declared themselves.

Labs at 3 months:

• Total testosterone (trough)
• Hematocrit and hemoglobin
• PSA
• Hepatic transaminases (ALT, AST)
• Estradiol (if symptoms of gynecomastia, nipple tenderness, or fluid retention are present)

Physical exam at 3 months:

• Blood pressure (testosterone can increase systolic BP by 3 to 5 mmHg)
• Weight and waist circumference
• DRE for men over 40 or men with elevated PSA
• Breast exam for gynecomastia
• Skin assessment of application site for contact dermatitis

A PSA velocity exceeding 1.4 ng/mL per year or an absolute PSA above 4.0 ng/mL should prompt urology referral and possible biopsy before continuing therapy. The American Urological Association emphasizes that TRT does not cause prostate cancer, but it may accelerate growth of occult, pre-existing disease.

The 6-Month Visit: Lipids, Liver, and Cardiovascular Risk

Six months is the point at which lipid changes become measurable. Testosterone tends to lower HDL by 5 to 10% and can modestly reduce LDL, creating a mixed cardiovascular signal. The TRAVERSE trial (N=5,246, published in the New England Journal of Medicine, 2023) showed that testosterone replacement did not significantly increase the incidence of major adverse cardiovascular events (MACE) compared to placebo over a mean follow-up of 33 months (hazard ratio 0.99, 95% CI 0.81 to 1.21). This was the first adequately powered RCT designed specifically to test cardiovascular safety of TRT.

Labs at 6 months:

• Total testosterone (trough)
• Hematocrit
• PSA
• Fasting lipid panel
• Hepatic transaminases
• Fasting glucose or HbA1c (testosterone may improve insulin sensitivity in hypogonadal men with type 2 diabetes, per a 2021 analysis in Diabetes Care)
• Estradiol (if dose was adjusted or aromatization symptoms emerged)

If hematocrit exceeds 54% at any point, current Endocrine Society guidance recommends withholding testosterone until hematocrit falls below 50%, then restarting at a lower dose or switching to a formulation with a lower polycythemia rate. Therapeutic phlebotomy (removing 1 unit of blood) is a common bridge intervention.

Annual Monitoring: The Long-Term Checklist

After the first year, stable patients need visits every 6 to 12 months. "Stable" means: testosterone is in the target range, hematocrit is below 50%, PSA velocity is below 0.75 ng/mL per year, and no new symptoms have appeared.

Annual labs:

| Test | Purpose | Action threshold | |---|---|---| | Total testosterone (trough) | Confirm absorption, dose adequacy | <400 or >700 ng/dL triggers dose change | | Hematocrit / CBC | Polycythemia screening | >54% = hold therapy | | PSA | Prostate safety | >4.0 ng/mL or velocity >1.4 ng/mL/yr = urology referral | | Fasting lipid panel | Cardiovascular risk | Treat per ACC/AHA lipid guidelines | | Hepatic panel | Hepatotoxicity screening | ALT >3x ULN = consider stopping | | HbA1c or fasting glucose | Metabolic effect tracking | Adjust diabetes regimen if improving | | Estradiol | Aromatization monitoring | >40 pg/mL with symptoms = dose reduction or aromatase inhibitor discussion |

Annual exams:

• Blood pressure
• DRE (men over 50 or men with a family history of prostate cancer)
• Breast exam
• BMI and body composition assessment

Dr. Shalender Bhasin, the principal investigator of the TTrials, noted in the study publication: "Monitoring should be systematic and sustained. The benefits of testosterone therapy accrue over years, and so do the risks if surveillance lapses" 1.

Bone Density: When to Order a DEXA Scan

Hypogonadism is one of the leading secondary causes of osteoporosis in men. The TTrials bone sub-study showed that 12 months of testosterone gel increased volumetric bone mineral density (vBMD) of the lumbar spine by 7.5% compared to placebo, measured by quantitative CT 2.

Order a baseline DEXA scan if the patient has:

• A fragility fracture history
• Chronic glucocorticoid use (prednisone 5 mg or more daily for 3+ months)
• A body weight below 154 lbs (70 kg)
• Age over 50 with additional risk factors

If baseline DEXA shows osteopenia or osteoporosis (T-score below -1.0 at any site), repeat DEXA at 1 to 2 years to document treatment response. The Endocrine Society does not recommend routine DEXA in hypogonadal men without risk factors.

Cardiovascular Monitoring: What Changed After TRAVERSE

Before 2023, testosterone therapy carried an FDA-mandated cardiovascular warning based on mixed observational data. TRAVERSE changed the evidence base. The trial enrolled men aged 45 to 80 with pre-existing cardiovascular disease or high cardiovascular risk and found no significant increase in MACE with testosterone replacement versus placebo over 33 months 3.

What clinicians should still monitor:

• Blood pressure at every visit (testosterone causes mild sodium and water retention)
• Lipid panel at 6 months and annually (HDL may drop, meaning net cardiovascular risk must be interpreted alongside LDL, triglycerides, and Lp(a))
• Edema and weight gain (common in the first 3 months)
• Sleep apnea symptoms (testosterone may worsen obstructive sleep apnea; a 2014 JAMA meta-analysis identified this association)

If the patient develops new-onset snoring, witnessed apneas, or excessive daytime sleepiness, refer for polysomnography before continuing therapy. Untreated severe OSA is a relative contraindication to TRT.

Secondary Exposure Monitoring: The Black-Box Warning

AndroGel carries an FDA black-box warning for secondary exposure. Testosterone can transfer from the patient's skin to a partner or child through direct contact, causing virilization in women and precocious puberty in children. The FDA safety communication documents cases of enlarged genitalia, advanced bone age, and aggressive behavior in children exposed through skin contact with treated adults.

Monitoring steps:

• Counsel the patient to wash hands immediately after application and cover the application site with clothing
• Ask about household contacts (children, pregnant partners) at every visit
• If a child or woman in the household develops signs of androgen excess (acne, voice deepening, body hair growth), check their serum testosterone immediately and discontinue AndroGel until the exposure source is controlled

When Labs Can Be Spaced Out: Criteria for De-Escalation

After 2 years of stable therapy (defined as: testosterone trough 400 to 700 ng/dL at two consecutive visits, hematocrit consistently below 50%, PSA stable, no new symptoms), the Endocrine Society permits extending the monitoring interval to every 12 months. Patients with polycythemia history, prostate concerns, or cardiovascular comorbidities should remain on 6-month intervals indefinitely.

Testosterone gel therapy is not a "set it and forget it" treatment. The 2018 Endocrine Society Clinical Practice Guideline states: "Clinicians should monitor patients receiving testosterone therapy using a standardized plan that includes assessment of symptoms, adverse effects, and laboratory tests at regular intervals." This means a minimum of one face-to-face visit per year, with labs drawn before the visit, for the entire duration of treatment.

Stopping AndroGel: What to Monitor During Discontinuation

If therapy is discontinued (patient choice, adverse effect, or fertility planning), expect serum testosterone to fall to pre-treatment levels within 1 to 3 weeks. The hypothalamic-pituitary-gonadal (HPG) axis, suppressed during exogenous testosterone use, may take 1 to 6 months to recover. LH and FSH typically begin rising within 4 weeks of cessation.

Post-discontinuation monitoring should include:

• Total testosterone at 4, 8, and 12 weeks
• LH and FSH at 4 and 12 weeks
• Symptom assessment (fatigue, mood changes, decreased libido are common during recovery)
• Hematocrit (should normalize; if it does not, evaluate for polycythemia vera)

For men discontinuing TRT to restore fertility, human chorionic gonadotropin (hCG) or clomiphene citrate may be used as bridge therapy under endocrinology supervision. Spermatogenesis typically recovers within 6 to 12 months of stopping exogenous testosterone, per a 2019 review in Fertility and Sterility.

Sample Monitoring Timeline: Year One at a Glance

| Timepoint | Labs | Exam | |---|---|---| | Baseline (pre-Rx) | 2x morning total T, free T/SHBG, CBC, PSA, lipids, LFTs, LH, FSH, estradiol, prolactin | BP, DRE (age >40), breast, BMI | | Week 2 to 4 | Trough total T, hematocrit | Application site check | | Month 3 | Trough total T, CBC, PSA, LFTs, estradiol (if indicated) | BP, DRE, breast, weight | | Month 6 | Trough total T, CBC, PSA, lipids, LFTs, HbA1c, estradiol | BP, DRE, breast, BMI, OSA screen | | Month 12 | Full annual panel (see table above) | Full annual exam, DEXA if indicated |

The single most important lab value to track is hematocrit. The single most important clinical question to ask is whether anyone in the household is showing signs of secondary testosterone exposure.